LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, and the California NanoSystems Institute at UCLA today announced a partnership designed to collaborate on early research in nanobiotechnology for the advancement of new technologies in medicine.
